Published in Mov Disord on March 01, 1996
Control of sleep and wakefulness. Physiol Rev (2012) 3.06
REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci (2010) 2.46
Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med (2010) 1.62
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Treatment of the sleep disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.95
Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep (2008) 0.94
REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging (2010) 0.93
Sleep disorders in multiple system atrophy. J Neural Transm (Vienna) (2005) 0.86
REM sleep behaviour disorder and visuoperceptive dysfunction: a disorder of the ventral visual stream? J Neurol (2009) 0.82
A network model of basal ganglia for understanding the roles of dopamine and serotonin in reward-punishment-risk based decision making. Front Comput Neurosci (2015) 0.80
Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. EPMA J (2011) 0.80
Parkinson's disease and sleep/wake disturbances. Parkinsons Dis (2012) 0.78
"I choked my wife again!"-a case report. Prim Care Companion CNS Disord (2011) 0.75
Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein. Diagnostics (Basel) (2013) 0.75
Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease. CNS Drugs (2017) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Idiopathic cervical dystonia: clinical characteristics. Mov Disord (1991) 2.21
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Functional brain networks in DYT1 dystonia. Ann Neurol (1998) 2.14
Oral and genital tardive pain syndromes. Neurology (1994) 2.07
What is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord (1991) 2.05
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 2.02
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol (1989) 2.00
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 1.97
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord (1994) 1.88
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem (1966) 1.86
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 1.77
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Delayed-onset cerebellar syndrome. Arch Neurol (1996) 1.65
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. J Biol Chem (1966) 1.62
Chronic manganese intoxication. Arch Neurol (1974) 1.61
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab (1993) 1.52
High dosage anticholinergic therapy in dystonia. Neurology (1983) 1.52
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol (1995) 1.51
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 1.50
Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology (1991) 1.46
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology (1981) 1.46
The clinical spectrum of posthypoxic myoclonus. Mov Disord (2000) 1.46
Movement disorder in reflex sympathetic dystrophy: a case proven to be psychogenic by surveillance video monitoring. Mov Disord (1997) 1.45
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology (1974) 1.44
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology (1979) 1.43
Welcome news about levodopa, but uncertainty remains. Ann Neurol (1998) 1.42
Regional distribution of gamma-aminobutyric acid (GABA) in brain of the rhesus monkey. J Neurochem (1968) 1.41
Tourette syndrome. Arch Neurol (1996) 1.39
Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology (1991) 1.39
Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology (1986) 1.38
Definition of dystonia and classification of the dystonic states. Adv Neurol (1976) 1.36
Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol (1997) 1.34
Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope (1986) 1.33
An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol (1988) 1.33
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology (2002) 1.32
Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet (1990) 1.31
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med (1980) 1.28
Primary sensory symptoms in parkinsonism. Neurology (1976) 1.26
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol (2000) 1.22
Normal pressure hydrocephalus and hypertensive cerebrovascular disease. Arch Neurol (1974) 1.19
Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol (1994) 1.19
The varied clinical expressions of dystonia. Neurol Clin (1984) 1.17
Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol (1979) 1.16
Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology (1995) 1.16
Normal pressure hydrocephalus and Parkinson's disease. J Neural Transm Suppl (1983) 1.16
The natural history of embouchure dystonia. Mov Disord (2001) 1.15
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope (1988) 1.14
Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov Disord (1996) 1.14
Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol (1989) 1.14
Fatigue in levodopa-naive subjects with Parkinson disease. Neurology (2008) 1.13
Treatment of vascular hemiballism and hemichorea. Neurology (1977) 1.13
Diagnostic criteria for dystonia in DYT1 families. Neurology (2002) 1.12
The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry (2002) 1.11
Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology (2003) 1.09
The effect of estrogen replacement on early Parkinson's disease. Neurology (1999) 1.07
Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation (1998) 1.06
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
Production of transgenic tropical maize with cryIAb and cryIAc genes via microprojectile bombardment of immature embryos. Theor Appl Genet (1999) 1.06
The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry (1991) 1.05
The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics (1999) 1.05
Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology (2000) 1.05
Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up. J Neurol Neurosurg Psychiatry (2004) 1.05
Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci (1971) 1.04
The phenomenology of tics. Mov Disord (1986) 1.04
Spread of symptoms in idiopathic torsion dystonia. Mov Disord (1995) 1.03
The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord (1990) 1.03
Evaluation of the pull test technique in assessing postural instability in Parkinson's disease. Neurology (2004) 1.03
"Tip-of-the-tongue" phenomenon in Parkinson disease. Neurology (1982) 1.02